Business
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif.,
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries \nAppointment Effective May 20, 2024\nSAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.\n\n \n \n \n \n \n \n\n \nMs. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and diagnostics industries. She served most recently as the head of Global Product Strategy for Roche Pharma, where she was responsible for lifecycle management, accelerating delivery of the company's medicines from development to commercialization, across five therapeutic areas. She was also accountable for delivering portfolio prioritization and integrated strategic plans across the company's entire portfolio. Prior to that, she served as global head of Diagnostics Partnering for Roche Diagnostics, with responsibility for driving growth through licensing deals and acquisitions. Over more than 16 years at Roche and Genentech, she served in a number of senior roles across therapeutic areas, including immunology, infectious disease, oncology, ophthalmology and hemophilia. She brings significant expertise and leadership experience in both launching and growing successful new medicines.\n\"I am confident that Cristin is the right leader for our commercial organization as BioMarin enters this next chapter, bringing to the company expertise in lifecycle management and a strong track record of delivering growth across multiple therapeutic areas, successfully advancing programs from development to commercialization across a broad portfolio,\" said Alexander Hardy, president and chief executive officer of BioMarin. \"Her deep experience in the biopharmaceutical industry will add to the great talent I have seen across the organization since joining several months ago. We look forward to welcoming her to BioMarin and to the important work we will do together for patients.\"\nMs. Hubbard started her career as a medicinal chemist at Theravance, before joining Roche and Genentech. She holds a bachelor's degree in Biochemistry and Molecular Biolo...